Patient-reported secondary efficacy endpoints showed significant improvements in SMF severity ( PR-SMFRS ; P = 0.009 for ATX-101 1 mg/cm ( 2 ) , P < 0.001 for ATX-101 2 mg/cm ( 2 ) vs. placebo ) and emotions and perceived self-image ( PR-SMFIS ; P < 0.001 ) .